Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hepatitis C (HCV) and diabetes mellitus are the two main health concerns that cause devastating health and financial worries worldwide. It has been observed in the past that both diseases have a high correlation that might be due to the abnormal conditions of the liver. But the mechanism of the prevalence of diabetes in patients with chronic HCV infection still remains unclear. In our study, we have investigated T2DM in the male and female patients at Lady Reading Hospital (LRH), Peshawar. The blood samples of both in- and outpatients were analysed in the PCR laboratories of LRH from December 2014 to April 2015. Great prevalence of diabetes in hepatitis C infected male and female patients was observed during this study. The data were collected from the patients through a preplanned questionnaire that included name of the patient, HCV, being diabetic, age, gender, location, educational background, family history of the disease, other diseases, and any treatments if taken. The results of our study have found 26.42% prevalence of T2DM in HCV infected patients. So we conclude that HCV infection may be one of the reasons that could lead to T2DM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394350PMC
http://dx.doi.org/10.1155/2017/2416281DOI Listing

Publication Analysis

Top Keywords

prevalence diabetes
12
hepatitis infected
8
infected patients
8
hcv infection
8
male female
8
female patients
8
patients
6
hcv
5
prevalence
4
diabetes type
4

Similar Publications

Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease.

Eur J Gastroenterol Hepatol

September 2025

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, The University of Jordan, Jordan University Hospital.

Aim: The purpose of our study was to evaluate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its associated risk factors in patients with inflammatory bowel disease (IBD).

Methods: This was a retrospective chart review of patients who underwent treatment for IBD at Jordan University Hospital between January 2013 and 2022. Case finding methods and clinical chart reviews were used to evaluate the clinical profile of patients with IBD.

View Article and Find Full Text PDF

Objective: To describe the sociodemographic and clinical characteristics of individuals exposed to smoking or biomass smoke and followed at primary health care (PHC) centers across three states in Brazil.

Methods: This was a cross-sectional multicenter study including patients followed at any of four PHC centers in Brazil. Patients ≥ 35 years of age who were smokers or former smokers, or were exposed to biomass smoke were included, the exception being those with physical/mental disabilities and those who were pregnant.

View Article and Find Full Text PDF

Background: Since Ludwig proposed the term "nonalcoholic steatohepatitis" (NASH) for this liver disease in 1980, there have been many advances in understanding it, including its epidemiology, pathogenesis, diagnostic methods, and treatment.

Objective: This literature review aims to discuss the most relevant aspects of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: The review included clinical studies from the following databases: Embase, PubMed, Scopus, Web of Science, Lilacs, Ovid, and Scopus.

View Article and Find Full Text PDF

Background: The prevalence of Metabolic Syndrome (MetS) increases with aging, significantly contributing to the rising burden of non-communicable diseases (NCDs). This study aimed to investigate over-time changes in the prevalence of MetS and its components among the elderly population of Iran.

Methods: We analyzed data from the 2016 and 2021 national STEPwise approach to non-communicable disease risk factor Surveillance (STEPS) for participants aged ≥65 who completed all three survey steps (questionnaire-based assessments, physical measurements, and laboratory tests) with no missing data on MetS components.

View Article and Find Full Text PDF

Motivation: Drug repositioning presents a streamlined and cost-efficient way to expand the range of therapeutic possibilities. Drugs with human genetic evidence are more likely to advance successfully through clinical trials towards FDA approval. Single gene-based drug repositioning methods have been implemented, but approaches leveraging a broad spectrum of molecular signatures remain underexplored.

View Article and Find Full Text PDF